Dynamical Electrophysiology and Neuropathology in Lewy's Bodies Disease (DYNAPATH-LB)

January 2, 2026 updated by: University Hospital, Strasbourg, France
Lewy body disease (LBD) is a neurodegenerative disorder that causes cognitive and behavioral problems. However, it is difficult to diagnose, and its pathophysiology is still not fully understood. The usual diagnostic criteria for LBD have excellent specificity but poor sensitivity. In particular, we lack paraclinical tests that can make a significant contribution. LBD patients may exhibit abnormalities in brain activity dynamics, which can be detected by EEG and may be linked to neuronal dysfunctions specific to the disease. The objective of this study is twofold: first, to assess the validity of this observation, that is, to confirm that the observed phenomenon is indeed linked to the pathophysiology of LBD, and second, to clarify the nature of these abnormalities by exploring the brain dynamics of LBD patients in greater detail.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Strasbourg, France, 67091
        • Recruiting
        • Service de psychiatrie de la personne âgée - CHU de Strasbourg - France
        • Contact:
        • Principal Investigator:
          • Ludovic DORMEGNY-JEANJEAN, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult subjects (≥18 years old) who participated in the Alpha-Lewy-MA cohort and underwent RT-QuIC analysis and underwent a standard EEG examination at HUS between January 1, 2012, and January 1, 2020.

Description

Inclusion Criteria:

  • Adult subjects (≥18 years old).
  • Subject who participated in the Alpha-Lewy-MA cohort and underwent RT-QuIC analysis.
  • Subject who underwent a standard EEG examination at HUS between January 1, 2012, and January 1, 2020.

Exclusion Criteria:

- Subject who expressed opposition to participating in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Parameter θ of dynamic fluidity of brain activity
Time Frame: Up to 12 months

Parameter θ of dynamic fluidity of brain activity (quantifying the system's ability to move away from its current configuration)

θ is used to measure something specific in the brain: how flexible its activity is.

Quantifying the system's ability to move away from its current configuration:

  • In plain words, θ tells us how much the brain can change from its current state.
  • High θ → brain is very flexible, can switch between states easily.
  • Low θ → brain is rigid, stays in the same pattern longer.
Up to 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 2, 2025

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

June 2, 2026

Study Registration Dates

First Submitted

January 2, 2026

First Submitted That Met QC Criteria

January 2, 2026

First Posted (Actual)

January 13, 2026

Study Record Updates

Last Update Posted (Actual)

January 13, 2026

Last Update Submitted That Met QC Criteria

January 2, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9691

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lewy Body Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe